Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,970 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.
Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asano T, Ogawa C, Abe H, Kato K, Hotta N, Shima T, Matsuura K, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Morishita A, Hidaka I, Moriya A, Tsuji K, Akahane T, Okubo T, Arai T, Kitamura M, Morita K, Kawata K, Tanaka Y, Kumada T, Iwakiri K; KTK49 Liver Study Group. Atsukawa M, et al. Among authors: asano t. Hepatol Res. 2022 Mar;52(3):235-246. doi: 10.1111/hepr.13739. Epub 2021 Dec 17. Hepatol Res. 2022. PMID: 34861090
Factors associated with sustained virological response in 24-week telaprevir-based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype.
Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y. Abe H, et al. Among authors: asano t. Hepatol Res. 2015 Apr;45(4):387-96. doi: 10.1111/hepr.12360. Epub 2014 Jul 18. Hepatol Res. 2015. PMID: 24849518
Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients.
Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y. Abe H, et al. Among authors: asano t. Gastroenterol Res Pract. 2014;2014:549709. doi: 10.1155/2014/549709. Epub 2014 Aug 14. Gastroenterol Res Pract. 2014. PMID: 25197269 Free PMC article.
Influencing factors on serum 25-hydroxyvitamin D3 levels in Japanese chronic hepatitis C patients.
Atsukawa M, Tsubota A, Shimada N, Yoshizawa K, Abe H, Asano T, Ohkubo Y, Araki M, Ikegami T, Kondo C, Itokawa N, Nakagawa A, Arai T, Matsushita Y, Nakatsuka K, Furihata T, Chuganji Y, Matsuzaki Y, Aizawa Y, Iwakiri K. Atsukawa M, et al. Among authors: asano t. BMC Infect Dis. 2015 Aug 19;15:344. doi: 10.1186/s12879-015-1020-y. BMC Infect Dis. 2015. PMID: 26286329 Free PMC article.
Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin.
Atsukawa M, Tsubota A, Shimada N, Yoshizawa K, Abe H, Asano T, Ohkubo Y, Araki M, Ikegami T, Okubo T, Kondo C, Osada Y, Nakatsuka K, Chuganji Y, Matsuzaki Y, Iwakiri K, Aizawa Y. Atsukawa M, et al. Among authors: asano t. Hepatol Res. 2016 Mar;46(5):450-8. doi: 10.1111/hepr.12575. Epub 2015 Sep 17. Hepatol Res. 2016. PMID: 26289410
Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C.
Atsukawa M, Tsubota A, Koushima Y, Ikegami T, Watanabe K, Shimada N, Sato S, Kato K, Abe H, Okubo T, Arai T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, Matsuzaki Y, Iwakiri K. Atsukawa M, et al. Among authors: asano t. Hepatol Res. 2017 Dec;47(13):1429-1437. doi: 10.1111/hepr.12910. Epub 2017 May 30. Hepatol Res. 2017. PMID: 28457003
Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema.
Atsukawa M, Tsubota A, Kato K, Abe H, Shimada N, Asano T, Ikegami T, Koeda M, Okubo T, Arai T, Nakagawa-Iwashita A, Yoshida Y, Hayama K, Itokawa N, Kondo C, Chuganji Y, Matsuzaki Y, Iwakiri K. Atsukawa M, et al. Among authors: asano t. J Gastroenterol Hepatol. 2018 Jun;33(6):1256-1263. doi: 10.1111/jgh.14047. Epub 2018 Feb 19. J Gastroenterol Hepatol. 2018. PMID: 29215154
Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease.
Arai T, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K. Arai T, et al. Among authors: asano t. Hepatol Res. 2018 Jun;48(7):549-555. doi: 10.1111/hepr.13058. Epub 2018 Feb 21. Hepatol Res. 2018. PMID: 29316062
Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
Toyoda H, Atsukawa M, Takaguchi K, Senoh T, Michitaka K, Hiraoka A, Fujioka S, Kondo C, Okubo T, Uojima H, Tada T, Yoneyama H, Watanabe T, Asano T, Ishikawa T, Tamai H, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Deguchi A, Itobayashi E, Mikami S, Moriya A, Okubo H, Tani J, Tsubota A, Tanaka Y, Masaki T, Iwakiri K, Kumada T. Toyoda H, et al. Among authors: asano t. J Gastroenterol. 2018 Dec;53(12):1276-1284. doi: 10.1007/s00535-018-1473-z. Epub 2018 May 8. J Gastroenterol. 2018. PMID: 29740665
2,970 results